Cat. No.: HY-13207

ONX-0914

(Synonyms: PR-957)

26 Cited Publications

Avis client

Based on 26 publication(s) in Google Scholar

ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.72%
CAS No.: 960374-59-8
Formule: C₃₁H₄₀N₄O₇
Masse moléculaire:580.67

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ONX-0914 Chemical Structure

CAS No.: 960374-59-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

HIV-1

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	EC₅₀	1.3 μM Compound: ONX-0914	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
Fibroblast	EC₅₀	0.16 μM Compound: ONX-0914	Cytotoxicity against human fibroblasts assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human fibroblasts assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
HCT-116	EC₅₀	0.11 μM Compound: ONX-0914	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
Huh-7	EC₅₀	0.39 μM Compound: ONX-0914	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
MCF7	EC₅₀	0.26 μM Compound: ONX-0914	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
MDA-MB-231	EC₅₀	0.27 μM Compound: ONX-0914	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
MM1.S	IC₅₀	0.24 μM Compound: 4; ONX-091	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 34087498]
NCI-H727	EC₅₀	0.3 μM Compound: ONX-0914	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
PBMC	IC₅₀	0.12 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-12/23 p40 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-12/23 p40 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	0.22 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced GMCSF production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced GMCSF production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	0.24 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	0.56 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNF-alpha production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNF-alpha production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	1.11 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	1.47 μM Compound: 3; ONX 0914; PR-957; LMP7	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced Il-1b production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced Il-1b production pretreated for 1 hr followed by LPS stimulation measured after 20 hrs	[PMID: 28435528]
PBMC	IC₅₀	3.4 μM Compound: 3; ONX 0914; PR-957; LMP7	Cytotoxicity against human PBMC assessed as decrease in cell viability by CellTiter-Glo assay Cytotoxicity against human PBMC assessed as decrease in cell viability by CellTiter-Glo assay	[PMID: 28435528]
PC-3	EC₅₀	0.33 μM Compound: ONX-0914	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by Hoechst 33342 staining based HCS assay	[PMID: 29339252]
Raji	IC₅₀	>10 μM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-1c in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry Inhibition of 20s proteasome subunit beta-1c in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry	[PMID: 25006746]
Raji	IC₅₀	0.46 μM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-1i in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry Inhibition of proteasome subunit beta-1i in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry	[PMID: 25006746]
Raji	IC₅₀	0.59 μM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-2i in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry Inhibition of proteasome subunit beta-2i in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry	[PMID: 25006746]
Raji	IC₅₀	1.1 μM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-2c in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry Inhibition of 20s proteasome subunit beta-2c in human Raji cells using BODIPY- epoxomicin by fluorescent densitometry	[PMID: 25006746]
Raji	IC₅₀	5.7 nM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-5i in human Raji cells using BODIPY-NC005 by fluorescent densitometry Inhibition of proteasome subunit beta-5i in human Raji cells using BODIPY-NC005 by fluorescent densitometry	[PMID: 25006746]
Raji	IC₅₀	54 nM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-5c in human Raji cells using BODIPY-NC005 by fluorescent densitometry Inhibition of 20s proteasome subunit beta-5c in human Raji cells using BODIPY-NC005 by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	>5 μM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-1c in human RPMI8226 cells using BODIPY-NC001 by fluorescent densitometry Inhibition of 20s proteasome subunit beta-1c in human RPMI8226 cells using BODIPY-NC001 by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	0.018 μM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-5i in human RPMI8226 cells using BODIPY-NC005 by fluorescent densitometry Inhibition of proteasome subunit beta-5i in human RPMI8226 cells using BODIPY-NC005 by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	0.18 μM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-5c in human RPMI8226 cells using BODIPY-NC005 by fluorescent densitometry Inhibition of 20s proteasome subunit beta-5c in human RPMI8226 cells using BODIPY-NC005 by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	0.34 μM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-1i in human RPMI8226 cells using BODIPY-NC001 by fluorescent densitometry Inhibition of proteasome subunit beta-1i in human RPMI8226 cells using BODIPY-NC001 by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	0.59 μM Compound: 1, ONX-0914	Inhibition of proteasome subunit beta-2i in human RPMI8226 cells using BODIPY-epoxomicin by fluorescent densitometry Inhibition of proteasome subunit beta-2i in human RPMI8226 cells using BODIPY-epoxomicin by fluorescent densitometry	[PMID: 25006746]
RPMI-8226	IC₅₀	0.68 μM Compound: 4; ONX-091	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 34087498]
RPMI-8226	IC₅₀	1.1 μM Compound: 1, ONX-0914	Inhibition of 20s proteasome subunit beta-2c in human RPMI8226 cells using BODIPY-epoxomicin by fluorescent densitometry Inhibition of 20s proteasome subunit beta-2c in human RPMI8226 cells using BODIPY-epoxomicin by fluorescent densitometry	[PMID: 25006746]

In Vitro

ONX-0914 inhibits LMP7-specific antigen presentation. ONX-0914 blocks cytokine productionby mouse splenocytes and blocks T celldifferentiation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ONX-0914 (2-10 mg/kg; i.v,; on days 4, 6 and 8) meliorates disease in mouse arthritis^[1].
? ONX-0914 (2, 6 and 10 mg per kg body weight on days 25, 27, 29, 31 and 33; i.v.) treatment also induced a rapid therapeutic response in the T and B cell–dependent CIA (collagen-induced arthritis) model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Collagen antibody-induced arthritis (CAIA, Arthritis was induced in BALB/c mice with antibodies specific for type II collagen (mAb) and endotoxin)^[1]
Dosage:

2, 6 or 10 mg per kg body weight
Administration:

I.v.; treated on days 4, 6 and 8
Result:

Blocked disease progression in a dose-dependent manner and completely ameliorated visible signs of disease at the highest dose.

Chemical Information

CAS No. 960374-59-8
Appearance Solid
Masse moléculaire 580.67
Formule C₃₁H₄₀N₄O₇
Color White to yellow
SMILES

O=C(N[C@@H](C)C(N[C@@H](CC1=CC=C(OC)C=C1)C(N[C@@H](CC2=CC=CC=C2)C([C@]3(C)OC3)=O)=O)=O)CN4CCOCC4
Synonyms

PR-957
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (26)

All WB

Sort by:

Journal Impact Factor

Cell

The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis. [Abstract]

2025 Aug 21;188(17):4567-4585.e32. PMID: 40532699
Mol Cancer

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. [Abstract]

2023 Dec 4;22(1):196. PMID: 38049829
Adv Mater

Differential Optical Imaging of Antigen Presentation Machinery Using Molecular Optical Reporters. [Abstract]

2025 Jul;37(30):e2420393. PMID: 40370186
Autophagy

Limiting cap-dependent translation increases 20S proteasomal degradation and protects the proteomic integrity in autophagy-deficient skeletal muscle. [Abstract]

2025 Jun;21(6):1212-1227. PMID: 39878121
Redox Biol

Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease. [Abstract]

2021 Nov:47:102167. PMID: 34662812
Cell Death Dis

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. [Abstract]

2022 Oct 8;13(10):860. PMID: 36209148
J Neuroinflammation

Targeting the immunoproteasome in hypothalamic neurons as a novel therapeutic strategy for high-fat diet-induced obesity and metabolic dysregulation. [Abstract]

2024 Aug 2;21(1):191. PMID: 39095788
J Med Chem

α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity. [Abstract]

2025 Dec 25;68(24):26405-26417. PMID: 41344819
Eur J Med Chem

Discovery of selective fragment-sized immunoproteasome inhibitors. [Abstract]

2021 Jul 5:219:113455. PMID: 33894528
Biochem Pharmacol

Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. [Abstract]

2020 Jul:177:113964. PMID: 32278007
Biochem Pharmacol

PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1. [Abstract]

2018 Oct:156:511-523. PMID: 30170098

ONX-0914 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Oct:156:511-523. [Abstract]

The accumulated poly-ubiquitinated protein is detected by Western blotting after J-Lat 10.6 cells are treated with DMSO, PR-957 (100 nM), PR-957 (150 nM) or MG132 (500 nM) for 48 h.

ONX-0914 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Oct:156:511-523. [Abstract]

Western blot detection of the p-TEFb component CDK9, Cyclin T1 and CDK9 phosphorylation on Thr186, as well as its downstream RNA poly II CTD and phosphate CTD after J-Lat 10.6 cells are treated with PR-957 in dose-dependent manner.

ONX-0914 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Oct:156:511-523. [Abstract]

J-Lat 10.6 cells are treated with DMSO, PR-957 (150 nM) or Carfilzomib (40 nM) alone with or without the HSF1 inhibitor KRIBB11 (1.25 µM) for 48 h. Then the cells are lysed, and Ser320 phosphorylated HSF1, total HSF1 and p24 are detected by Western blot with the corresponding antibodies.
Cells

Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads. [Abstract]

2021 Dec 6;10(12):3431. PMID: 34943940
Int Immunopharmacol

Different roles of bortezomib and ONX 0914 in acute kidney injury. [Abstract]

2020 Mar 3;82:106259. PMID: 32143000
Am J Physiol Cell Physiol

Immunoproteasome subunit PSMB8 promotes skeletal muscle regeneration by regulating macrophage phenotyping switch in mice. [Abstract]

2025 Apr 16. PMID: 40241316
Molecules

Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome. [Abstract]

2020 Mar 12;25(6):1305. PMID: 32178473
Sci Rep

Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. [Abstract]

2025 May 19;15(1):17284. PMID: 40389585
Sci Rep

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein. [Abstract]

2021 May 25;11(1):10883. PMID: 34035431
Comput Struct Biotechnol J

PDGF-D-induced immunoproteasome activation and cell-cell interactions. [Abstract]

2023 Mar 28:21:2405-2418. PMID: 37066124
Oncol Res

Inhibition of Proteasome LMP2 Activity Suppresses Chil3 Expression in Mouse Colon Adenocarcinoma Tissue and Restrains Tumor Growth. [Abstract]

2025 Aug 28;33(9):2573-2595. PMID: 40918453
Neuroscience

PR-957 Suppresses Th1 and Th17 Cell Differentiation via Inactivating PI3K/AKT Pathway in Alzheimer's Disease. [Abstract]

2023 Feb 1:510:82-94. PMID: 36581132
Curr Protoc

2025 Dec 13.
Curr Protoc

Synthesis and Application of a Caged Bioluminescent Probe for the Immunoproteasome. [Abstract]

2024 Nov;4(11):e70057. PMID: 39574360
Neuroreport

Inhibition of immunoproteasome subunit low molecular mass polypeptide 7 with ONX-0914 improves hypoxic-ischemic brain damage via PI3K/Akt signaling. [Abstract]

2021 Oct 6;32(14):1206-1215. PMID: 34406990
University of California, Irvine

2026.
bioRxiv

Dissecting Complex Interactions Between Ferroptosis and the Proteasome. [Abstract]

2026 Mar 30:2026.03.28.714855. PMID: 41959534
Evid Based Complement Alternat Med

Inhibition of the Immunoproteasome Subunit LMP7 Ameliorates Cerebral White Matter Demyelination Possibly via TGF β/Smad Signaling. [Abstract]

2021 Oct 12:2021:6426225. PMID: 34675988

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (172.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7221 mL

8.6107 mL

17.2215 mL

5 mM

0.3444 mL

1.7221 mL

3.4443 mL

10 mM

0.1722 mL

0.8611 mL

1.7221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Muchamuel T, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis [published correction appears in Nat Med. 2009 Nov;15(11):1333]. Nat Med. 2009;15(7):781-787. [Content Brief]

[2]. Rožman K, et al. Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome. Molecules. 2020;25(6):1305. Published 2020 Mar 12. [Content Brief]

[3]. Lin J, et al. PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1. Biochem Pharmacol. 2018;156:511-523. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7221 mL	8.6107 mL	17.2215 mL	43.0537 mL
	5 mM	0.3444 mL	1.7221 mL	3.4443 mL	8.6107 mL
	10 mM	0.1722 mL	0.8611 mL	1.7221 mL	4.3054 mL
	15 mM	0.1148 mL	0.5740 mL	1.1481 mL	2.8702 mL
	20 mM	0.0861 mL	0.4305 mL	0.8611 mL	2.1527 mL
	25 mM	0.0689 mL	0.3444 mL	0.6889 mL	1.7221 mL
	30 mM	0.0574 mL	0.2870 mL	0.5740 mL	1.4351 mL
	40 mM	0.0431 mL	0.2153 mL	0.4305 mL	1.0763 mL
	50 mM	0.0344 mL	0.1722 mL	0.3444 mL	0.8611 mL
	60 mM	0.0287 mL	0.1435 mL	0.2870 mL	0.7176 mL
	80 mM	0.0215 mL	0.1076 mL	0.2153 mL	0.5382 mL
	100 mM	0.0172 mL	0.0861 mL	0.1722 mL	0.4305 mL

Keywords

ONX-0914

26 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

ONX-0914

Covalent Screening Library

Antibacterial Compound Library

Ubiquitination Compound Library

Anti-Blood Cancer Compound Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) ONX-0914

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (26)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ONX-0914

Covalent Screening Library

Antibacterial Compound Library

Ubiquitination Compound Library

Anti-Blood Cancer Compound Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) ONX-0914

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (26)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ONX-0914 Related Classifications

HY-13207 Related Classifications